News Quantified

CRSP – crispr therapeutics ag - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

CRISPR Therapeutics Milestones And ARK Backing Contrast With Valuation Gap [Yahoo! Finance]

CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Citizens Jmp from $86.00 to $80.00. They now have a "market outperform" rating on the stock.

CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..

Forget AI Stocks: This Biotech Could Cure What AI Can't Touch [Yahoo! Finance]

BofA is Bullish on CRISPR Therapeutics AG (CRSP) [Yahoo! Finance]

-6.2%

BEAT

-7.1%

MISS

Market Outperform

Market Outperform

Needham & Company LLC

Chardan Capital

Form 4 CRISPR Therapeutics AG For: Apr 03 Filed by: Patel Naimish

Form 4 CRISPR Therapeutics AG For: Jan 22 Filed by: Prasad Raju

Form 4 CRISPR Therapeutics AG For: Jan 20 Filed by: Kulkarni Samarth

Form 144 CRISPR Therapeutics AG Filed by: Kulkarni Samarth

Form 144 CRISPR Therapeutics AG Filed by: Prasad Raju

Top News Gainers

11/19 CRISPR Therapeutics down 4% premarket on initial CTX001 data [Seeking Alpha] 19.1%

2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%

10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%

8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%

2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%

12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%

11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%

10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%

6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%

4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%

Top News Decliners

11/20 CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares -10.6%

3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%

8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%

12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%

12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%

2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%

10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%

9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%

2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%

6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day